• Home
  • Search Results
  • Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.

Structure-activity relationship of S-trityl-L-cysteine analogues as inhibitors of the human mitotic kinesin Eg5.

Journal of medicinal chemistry (2008-02-13)
Salvatore Debonis, Dimitrios A Skoufias, Rose-Laure Indorato, François Liger, Bernard Marquet, Christian Laggner, Benoît Joseph, Frank Kozielski
ABSTRACT

The human kinesin Eg5 is a potential drug target for cancer chemotherapy. Eg5 specific inhibitors cause cells to block in mitosis with a characteristic monoastral spindle phenotype. Prolonged metaphase block eventually leads to apoptotic cell death. S-trityl-L-cysteine (STLC) is a tight-binding inhibitor of Eg5 that prevents mitotic progression. It has proven antitumor activity as shown in the NCI 60 tumor cell line screen. It is of considerable interest to define the minimum chemical structure that is essential for Eg5 inhibition and to develop more potent STLC analogues. An initial structure-activity relationship study on a series of STLC analogues reveals the minimal skeleton necessary for Eg5 inhibition as well as indications of how to obtain more potent analogues. The most effective compounds investigated with substitutions at the para-position of one phenyl ring have an estimated K i (app) of 100 nM in vitro and induce mitotic arrest with an EC 50 of 200 nM.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Triphenylmethanol, 97%
Sigma-Aldrich
Trityl chloride, 97%
Sigma-Aldrich
Triphenylmethanethiol, 97%
Sigma-Aldrich
(+)-S-Trityl-L-cysteine, 97%
Sigma-Aldrich
Bromotriphenylmethane, 98%
Sigma-Aldrich
Triphenylmethylamine, 99%
Sigma-Aldrich
4-Tritylaniline, 97%

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.